PMV Pharmaceuticals Inc
NASDAQ:PMVP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Noble Helium Ltd
ASX:NHE
|
AU |
|
K3 Business Technology Group PLC
LSE:KBT
|
UK |
|
S
|
SmartDrive Inc
TSE:5137
|
JP |
|
Turkiye Vakiflar Bankasi TAO
IST:VAKBN.E
|
TR |
|
A
|
Arabian Food & Dairy Factories Company
SAU:9536
|
SA |
|
R
|
Rich Goldman Holdings Ltd
HKEX:70
|
HK |
PMV Pharmaceuticals Inc
Research & Development
PMV Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PMV Pharmaceuticals Inc
NASDAQ:PMVP
|
Research & Development
-$69.9m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
PMV Pharmaceuticals Inc
Glance View
PMV Pharmaceuticals, Inc. engages in the development of p53 targeted small molecule drugs for the treatment of cancer. The company is headquartered in Cranbury, New Jersey and currently employs 54 full-time employees. The company went IPO on 2020-09-25. The Company’s lead product candidate, PC14586, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. PC14586 is designed to restore the wild-type conformation by occupying the crevice created by the tyrosine to cysteine mutation in amino acid position 220. The firm is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates, which structurally correct other p53 hotspot mutations to restore their wild-type function and product candidates that target certain cancers where wild-type p53 function is silenced.
See Also
What is PMV Pharmaceuticals Inc's Research & Development?
Research & Development
-69.9m
USD
Based on the financial report for Dec 31, 2025, PMV Pharmaceuticals Inc's Research & Development amounts to -69.9m USD.
What is PMV Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-24%
Over the last year, the Research & Development growth was -19%. The average annual Research & Development growth rates for PMV Pharmaceuticals Inc have been -10% over the past three years , -24% over the past five years .
